Ginkgo to acquire Bayer's agricultural biologics R&D platform for ~$83M

Ginkgo Bioworks Holdings, Inc.

Ginkgo acquires Bayer's 175,000 sq ft West Sacramento Biologics R&D site and team for ~$83M in cash or stock.
Three-year strategic partnership with Bayer on nitrogen fixation, crop protection, and carbon sequestration.
Ginkgo to also integrate Joyn Bio R&D platform assets; deal expected to close Q4 2022.
Ginkgo may earn royalties on net sales from products developed under the Bayer collaboration.
Expands Ginkgo's agricultural biologicals platform; cash proceeds from collaboration offset acquired expenses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.